Dear Author,

Here are the proofs of your article.

- You can submit your corrections online, via e-mail or by fax.
- For online submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and email the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the journal title, article number, and your name when sending your response via e-mail or fax.
- Check the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- Check the questions that may have arisen during copy editing and insert your answers/corrections.
- Check that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the Edited manuscript.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please do not make changes that involve only matters of style. We have generally introduced forms that follow the journal’s style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections within 48 hours, we will send you a reminder.
- Your article will be published Online First approximately one week after receipt of your corrected proofs. This is the official first publication citable with the DOI. Further changes are, therefore, not possible.
- The printed version will follow in a forthcoming issue.

Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: http://dx.doi.org/[DOI]. If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: http://www.link.springer.com.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.
Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function

The Author(s)

(This will be the copyright line in the final PDF)

Inflammopharmacology

Tambuwala

Murtaza M.

SAAD Centre for Pharmacy and Diabetes, School of Pharmacy and Pharmaceutical Science

Ulster University

Coleraine, County Londonderry, BT52 1SA, Northern Ireland, UK

+44 28-701-24016

m.tambuwala@ulster.ac.uk

Khan

Mohammed N.

SAAD Centre for Pharmacy and Diabetes, School of Pharmacy and Pharmaceutical Science

Ulster University

Coleraine, County Londonderry, BT52 1SA, Northern Ireland, UK

Lane

Majella E.

UCL School of Pharmacy

29-39 Brunswick Square, London, WC1N 1AX, UK
Abstract

Background: Inhibition of the nuclear factor kappa beta (NF-κβ) pathway has been proposed as a therapeutic target due to its key role in the expression of pro-inflammatory genes, including pro-inflammatory cytokines, chemokines, and adhesion molecules. Caffeic acid phenethyl ester (CAPE) is a naturally occurring anti-inflammatory agent, found in propolis, and has been reported as a specific inhibitor of NF-κβ. However, the impact of CAPE on levels of myeloperoxidases (MPO) and pro-inflammatory cytokines during inflammation is not clear. The aims of this study were to investigate the protective efficacy of CAPE in the mouse model of colitis and determine its effect on MPO activity, pro-inflammatory cytokines levels, and intestinal permeability.

Method:
Dextran sulphate sodium was administered in drinking water to induce colitis in C57/BL6 mice before treatment with intraperitoneal administration of CAPE (30 mg kg⁻¹ day⁻¹). Disease activity index (DAI) score, colon length and tissue histology levels of MPO, pro-inflammatory cytokines, and intestinal permeability were observed.

Results:
CAPE-treated mice had lower DAI and tissue inflammation scores, with improved epithelial barrier protection and significant reduction in the level of MPO and pro-inflammatory cytokines.

Conclusion:
Our results show that CAPE is effective in suppressing inflammation-triggered MPO activity and pro-inflammatory cytokines production while enhancing epithelial barrier function in experimental colitis. Thus, we conclude that CAPE could be a potential therapeutic agent for further clinical investigations for treatment of inflammatory bowel diseases in humans.

Keywords (separated by '-')
Inflammatory bowel diseases - Colitis - Natural - Nuclear factor kappa beta - Pro-inflammatory cytokines - Intestinal permeability
Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function

Mohammed N. Khan1 · Majella E. Lane2 · Paul A. McCarron1 · Murtaza M. Tambuwala1

Received: 6 April 2017 / Accepted: 15 May 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Background Inhibition of the nuclear factor kappa beta (NF-κB) pathway has been proposed as a therapeutic target due to its key role in the expression of pro-inflammatory genes, including pro-inflammatory cytokines, chemokines, and adhesion molecules. Caffeic acid phenethyl ester (CAPE) is a naturally occurring anti-inflammatory agent, found in propolis, and has been reported as a specific inhibitor of NF-κB. However, the impact of CAPE on levels of myeloperoxidases (MPO) and pro-inflammatory cytokines during inflammation is not clear. The aims of this study were to investigate the protective efficacy of CAPE in the mouse model of colitis and determine its effect on MPO activity, pro-inflammatory cytokines levels, and intestinal permeability.

Method Dextran sulphate sodium was administered in drinking water to induce colitis in C57/BL6 mice before treatment with intraperitoneal administration of CAPE (30 mg kg⁻¹ day⁻¹). Disease activity index (DAI) score, colon length and tissue histology levels of MPO, pro-inflammatory cytokines, and intestinal permeability were observed.

Results CAPE-treated mice had lower DAI and tissue inflammation scores, with improved epithelial barrier protection and significant reduction in the level of MPO and pro-inflammatory cytokines.

Conclusion Our results show that CAPE is effective in suppressing inflammation-triggered MPO activity and pro-inflammatory cytokines production while enhancing epithelial barrier function in experimental colitis. Thus, we conclude that CAPE could be a potential therapeutic agent for further clinical investigations for treatment of inflammatory bowel diseases in humans.

Keywords Inflammatory bowel diseases · Colitis · Natural · Nuclear factor kappa beta · Pro-inflammatory cytokines · Intestinal permeability

Introduction

Inflammatory bowel disease (IBD) is an idiopathic disorder, generally categorised as either Crohn’s disease (CD) or ulcerative colitis (UC) (Neurath 2014; Ford et al. 2011). There is no therapeutic cure for IBD and the current disease management strategies possess several drawbacks. For example, immunomodulatory agents, such as azathioprine and 6-mercaptopurine, cause bone marrow depletion and damage to both white blood cell and hepatic cell populations. Furthermore, results from recent clinical trials confirm that azathioprine is ineffective in UC (Ardizzzone et al. 2006; Kamath et al. 2016; O’Connor et al. 2010) and sulfasalazine causes ruptures in liver tissue and decreases platelets count in blood (de Abajo et al. 2004; Rubin 1994). Furthermore, pulmonary disorders are reported in IBD patients treated with chimeric monoclonal antibodies, such as infliximab (Patel et al. 2016).
The clinical symptoms of IBD range from episodes of relapse and remission with mild inflammation and discomfort to a chronic ulcerative disease requiring surgical removal of the inflamed gut. The current therapeutic strategies for IBD are generally limited, but recent clinical advancement has occurred in immunotherapy using monoclonal antibodies. This approach is directed against inflammatory mediators, such as TNF-α (Targan 2006; Subramanian et al. 2017; Gecse and Lakatos 2017; Chan and Ng 2017). However, these biological agents are expensive and result in side effects and life-threatening complications (Cote-Daigneault et al. 2015; Blonski and Lichtenstein 2006; Clarke and Regueiro 2012; Cohen and Thomas 2006). Hence, there is a need in the field of IBD therapy to develop new therapeutics, which are effective, safe, and economical. One way to achieve this is investigation into the anti-inflammatory effect of natural compounds and understanding their mechanism of action. Lack of specificity and the encumbrance of severe side effects necessitate further investigation into effective and safer options for treating IBD (Pichai and Ferguson 2012), which is the aim of this current study.

Colonic specimens from UC patients display overexpression of transcription factor nuclear factor kappa beta (NF-κβ) (Atreya et al. 2008). NF-κβ is up regulated by TNF-α, interleukin (IL), interferon, chemokines, and DNA damaging agents during the inflammatory phase. Similar effects are observed following exposure to lipopolysaccharide derived from bacterial cell wall components (Lawrence 2009b; Xavier and Podolsky 2007). In UC, levels of inflammatory mediators, such as TNF-α, interleukins, and interferons, increase due to the over stimulation of NF-κβ during inflammation (Schreiber et al. 1998). It is feasible, therefore, that inhibition of NF-κβ may be of therapeutic benefit in UC, which forms the hypothesis of our current work.

Novel pharmacological inhibitors of NF-κβ are currently available, but these compounds inflect toxicity and severe side effects in humans. Hence, we have selected caffeic acid phenethyl ester (CAPE), a phenolic constituent derived from honeybee propolis and shown in Fig. 1, for further study. It possesses no known adverse side effects (Tolba et al. 2014; Liao et al. 2003). CAPE possesses potent anti-inflammatory properties, which are attributed to its selective inhibition of NF-κβ. Recently, CAPE has been reported to inhibit other relevant pathways, such as MAPK and PI3K (Natarajan et al. 1996; Ozturk et al. 2012; Lin et al. 2013; Pramanik et al. 2013; Cho et al. 2014). CAPE represses translocation of NF-κβ, either by inhibition of Ikβ degradation or by blocking of NF-κβ and DNA binding (Wang et al. 2010; Bezerra et al. 2012). It has been reported that inflammatory markers, such as INF-γ, IL-6, IL-β, TNF-α, and IL-10, cause degradation of Ikβ, which results in induced overexpression of NF-κβ (Lang et al. 2004). CAPE inhibits this overexpression of NF-κβ via prevention of degradation of Ikβ (Wang et al. 2010; Lee et al. 2008).

The most recent evaluation of the anti-inflammatory activity of CAPE has been limited to either cell culture models or rat models of 2,4,6-trinitrobenzenesulfonic acid-peptidoglycan polysaccharide-induced UC (Armutcu et al. 2015; Ek et al. 2008; Fitzpatrick et al. 2001; Kim et al. 2013). However, the pathophysiological mechanism, such as macroscopic, microscopic changes in the colon and effect on pro-inflammatory cytokine levels, and mucosal barrier function, by which CAPE exerts its anti-inflammatory activity, have not been fully explored (Fitzpatrick et al. 2001; Michaluart et al. 1999; Ek et al. 2008; Cooper et al. 1993). Hence, the activity of CAPE has not been studied in relevant in vivo models, which are physiologically more representative of the human disease (Chassaing et al. 2014a). Thus, the main aspect of this study, which differentiates it from the previous work, is assessment of the activity of CAPE on the colon at macroscopic and microscopic levels, its effect on MPO and pro-inflammatory cytokine levels and altered mucosal permeability in a mouse model of colitis, which is physiologically relevant to human disease (Tambuwala et al. 2015). The findings of this study will provide an insight into the anti-inflammatory efficacy of CAPE during colitis in terms of changes in the levels of the disease activity index (DAI) score, colon MPO, pro-inflammatory cytokines, and epithelial barrier function.

Materials and methods

Materials

Caffeic acid phenethyl ester (97%) was purchased from Sigma-Aldrich Ltd. (Dorset, UK) and dextran sodium sulphate (DSS) was procured from MP Biomedicals (Bedford, UK) (molecular weight 36,000–50,000). CAPE was administered by IP injection at a dose of 30 mg kg⁻¹ on a daily basis for 7 days. The injection was prepared by dissolving CAPE (1.0 mg) in 1.0 ml of sterile aqueous solution containing 25% PEG 200.

Fig. 1 Chemical structure of caffeic acid phenethyl ester (CAPE)
Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction of NF-kB levels in colon tissue

Dextran sodium sulphate model of induced colitis

For DSS colitis-induced experiments, 12-week-old C57BL/6 female mice were used (Charles River, UK). The Ulster University Animal Research Ethics Committee and UK Home Office approved all procedures described, under Project license (PL2768).

Colitis was induced by administering 2.5% w/v DSS in drinking water over a period of 7 days. The DAI score was used to record morphological changes, such as weight loss, stool consistency, and presence of blood in faeces. On termination of the experiment, mice were sacrificed by cervical dislocation (Egger et al. 2000; Okayasu et al. 1990). The isolated colon was excised, washed in PBS, and laid flat on moist tissue to measure its length. Sections, approximately 1.0 cm, of excised colonic tissue were fixed in 10% paraformaldehyde (pH 7.4; phosphate-buffered saline) and embedded in paraffin. Sections (4 μm) were cut and stained with haematoxylin and eosin. Histologic assessment and scoring of colon tissue sections were carried out in a blinded fashion based on previously defined parameters (Sutherland et al. 1987). All tissue slides were imaged using light a microscopy at 5× and 10× magnifications.

Colon cytokine and myeloperoxidases measurements

Post-mortem colon tissue was homogenised using a method adapted from processing lung tissue (Mangan et al. 2006). Levels of pro-inflammatory cytokines, such as INF-γ, IL-6, IL-1β, TNF-α, and IL-10, were detected using V-Plex Assay Plates (Meso Scale Diagnostics; Rockville, MD, USA) and assayed as per the manufacturer’s protocol. MPO activity was detected using o-phenylenediamine dihydrochloride as substrate and the data were interpolated from an MPO standard curve (Sigma). Levels of cytokines and MPO were expressed as pg per mg or U per mg, respectively, relative to colon protein (Cummins et al. 2008).

Assessment of NF-κB activation in colon tissue

Colon tissue was homogenised and lysate then analysed for NF-κB/p65 levels using a Nuclear Extraction kit (ActiveMotif, Carlsbad, USA) in accordance with the manufacturer’s protocol (Lin et al. 2014).

In vivo intestinal permeability measurements

Mice were exposed to 7 days of DSS treatment, which was followed by standard oral gavage of fluorescein isothiocyanate (FITC)-labelled dextran (4 kDa) at a dose of 0.6 mg g⁻¹ of body weight. Mice were euthanised 4 h later and blood removed by cardiac puncture. Plasma was separated and FITC levels in plasma determined by fluorometry (Tambuwala et al. 2010).

Statistical analysis

Results were expressed as mean ± standard error of the mean (SEM) for a series of experiments. Data were assumed to be normally distributed and statistical analyses were carried out using Prizm GraphPad V6 software (GraphPad, San Diego, CA, USA). A paired t test was used for comparisons of paired treatments between two groups, unpaired t tests for comparisons of unpaired treatments between two groups, and one-way ANOVA using Bonferroni multiple comparisons tests for treatments of three groups or more. P values ≤0.05 were considered to be significant.

Ethical considerations

The Ulster University Animal Research Ethics Committee and UK Home Office approved all procedures described, under Project license (PL2768). Severity levels were graded as mild by the UK home office.

Results

CAPE ameliorates disease in DSS-induced colitis

It has been reported by us and several researchers that colitis is a collection of symptoms, such as weight loss, diarrhoea, and blood in faeces, collectively described by the DAI and shortening of colon length (Ogawa et al. 2004; Taghipour et al. 2016; Chassaing et al. 2014b; Chen et al. 2007). To study the protective effect of CAPE on mice with DSS-induced colitis, we recorded the weight of each mouse in all groups daily for 7 days. Figure 2a shows significantly (P < 0.001) lowered weight loss in DSS + CAPE-treated mice when compared to the DSS-only group. Similarly, Fig. 2b shows that mice in the DSS-alone group had the highest DAI score, which confirmed the development of colitis. Mice treated with CAPE showed a significantly (P < 0.01) lower DAI score, when comparison is made to the DSS-only group. This finding suggests that CAPE was protecting mice against weight loss and the occurrence of diarrhoea and appearance of blood in faeces during DSS-induced colitis.

Shortening of the colon is one of the clinical signs of colitis (Tambuwala et al. 2015). Figure 3a shows representative image from the colon of a healthy mouse with well-formed stool pellets. In contrast, there were no formed stools and blood observed in the colon of mice treated with
DSS alone. However, semi-formed stools and no blood were visible in the colon of mouse treated with CAPE. A graphical presentation of the average colon length of each group is shown in Fig. 3b. It was observed that there was significant (P < 0.001) reduction in colon length in mice treated with DSS alone when compared to the healthy control and DSS + CAPE-treated mice. Thus, CAPE treatment attenuated the impact of DSS on colon length reduction and also assisted stool formation.

Histological examination of colon tissue confirmed that DSS treatment caused extensive colonic damage with loss of epithelium and collapse of crypt structure. This was accompanied by oedema and infiltration of inflammatory neutrophils (Fig. 4a). In contrast, there was a marked reduction in severity of DSS-induced colon injury in CAPE-treated mice. The crypt architecture showed that no ulceration or evidence of oedema, lesser degree of infiltration of inflammatory cells, and neutrophils were present in CAPE-treated group compared to DSS alone.
observed in the colon histology of mice receiving CAPE treatment (Fig. 4a). The blinded histological scoring of colon tissue histology revealed a significant reduction of damage in the colon of CAPE-treated mice relative to healthy control mice ($P < 0.001$; Fig. 4b). To confirm that CAPE downregulated the NF-κB pathway in DSS-induced colitis, we assessed the levels of p65 in colon tissue. There was a marked increase in the level of p65 in DSS-alone group and the mice treated with CAPE showed a significant reduction in the level of p65 (Supplementary Figure 1).

We next investigated the impact of CAPE treatment of the expression of markers of colonic inflammation that are increased in mice exposed to DSS. DSS-alone control mice showed a significant increase in MPO activity, a marker for inflammation, and leukocyte infiltration ($P < 0.01$; Fig. 5a). However, exposure of CAPE-treated mice to DSS did not result in increased colon MPO levels (Fig. 5a). We also noted that colonic levels of pro-inflammatory cytokines, such as INF-γ, IL6, IL1-β, TNF-α, and IL10 (Fig. 5b–e), were significantly ($P < 0.001$) increased in mice with DSS-induced colitis, as compared to healthy mice. Co-administration of CAPE resulted in small increases in INF-γ, IL1-β, TNF-α, and IL10, which were not significantly different from that of the healthy control. Thus, the DSS-induced colitis resulted in an increase in MPO, INF-γ, IL6, IL1-β, TNF-α, and IL10. All were diminished significantly in CAPE-treated mice ($P < 0.01$–0.001). Although IL-10 is known to play a protective role in colitis, we observed a small decrease in IL-10 levels in mice treated with CAPE, which was expected as CAPE is known to lower the levels of IL-10 (Sy et al. 2011). Furthermore, treatment of mice with CAPE alone had no effects on MPO, INF-γ, IL6, IL1-β, and TNF-α (data not shown).

**Enhanced epithelial barrier function in mice treated with CAPE**

To investigate the effect of CAPE treatment on the intestinal epithelial integrity, in vivo barrier function was measured in healthy mice, mice exposed to DSS and mice co-treated with CAPE and DSS. An oral dose of FITC-dextran was administered to mice on the last day of DSS exposure. Four hours later, FITC levels in plasma were determined as a measure of intestinal permeability. The DSS-only group of mice exhibited a significant increase in intestinal permeability, which was reflected by an increased appearance of FITC in plasma. This effect was markedly diminished in mice treated with CAPE (Fig. 6a; $P < 0.001$), indicating that co-treatment with CAPE during DSS-induced colitis reduces the leakiness of the colon and maintains the epithelial barrier function.

**Discussion**

The previous studies have indicated that CAPE is an effective inhibitor of NF-κB and related cytokines in vitro, and also has the ability induce apoptosis in...
inflammatory cells (Fitzpatrick et al. 2001). In our current study, we have shown for the first time that CAPE significantly ameliorates the severity of the disease in a mouse model of UC.

One of the initial events that occur during the onset of IBD is disruption of the intestinal epithelial barrier function. This dysfunction leads to unwanted movement of luminal antigenic material into the lamina propria. This is

Fig. 5 Effect of CAPE on expression of pro-inflammatory mediators. The colon tissue homogenates analysed for a MPO, b INF-γ, c IL-6, d IL-β, e TNF-α, and f IL-10. N = 5–6 mice per group (P < 0.001)
followed by activation of mucosal immune cells and triggering of an inflammatory response. It has been suggested that one of the critical events in the development of inflammation in the intestine could be the regulation of intestinal epithelial cell apoptosis (Cummins et al. 2008; Tambuwala et al. 2010). In cases of chronic inflammation during IBD, constant intestinal epithelial cell apoptosis could lead the loss of the epithelial barrier, which will result in spread of inflammation, resulting in increased severity of the disease. This creates an imbalance in the innate and adaptive immunity of the gut (Nenci et al. 2007; Zaph et al. 2007).

In the present work, we have shown for the first time that CAPE, a potent inhibitor NF-κB, is profoundly protective in an in vivo mouse model of acute colonic inflammation. Although we hypothesise that the protective effects of CAPE are mediated through the inhibition of the over activation of the NF-κB pathway, we cannot exclude the possibility of NF-κB independent mechanisms of action, such as inhibition of hydroxylases and activation of hypoxia inducible pathways (Cummins et al. 2008).

However, several researchers have indicated that the NF-κB pathway plays an important role during intestinal inflammation (Wei and Feng 2010; Buhrmann et al. 2011; Lawrence 2009a; Fitzpatrick et al. 2001) and inhibition of this pathway targets pro-inflammatory cytokines, such as interferons and tumour necrosis factor alpha. These are known to play key role during the development and progression of UC (Baird et al. 2016; Bishop et al. 2014; Ferrari et al. 2016).

CAPE treatment significantly ameliorated the severity of disease after acute DSS exposure in all parameters studied, including weight loss (Fig. 2a), clinical DAI score (Fig. 2b), reduction of colon length, and appearance of blood in faeces (Fig. 3a, b). A marked improvement in colon histology was observed (Fig. 4a), together with improved blinded inflammation scores (Fig. 4b). In the murine model of DSS-induced colitis, the increase in MPO and pro-inflammatory cytokines occurred after the disruption to the intestinal barrier, indicating that compromised barrier function results in progression inflammation. CAPE-treated mice did not have increased MPO (Fig. 5a) and only small increase in other pro-inflammatory cytokines (Fig. 5b–f), suggesting that CAPE treatment prevented the damage to epithelial cells caused by DSS and helps in maintaining the epithelial barrier function, which is evident by reduced permeability of FITC in mice treated with CAPE (Fig. 6). However, whether improved epithelial barrier function or indeed lowered cytokine expression is the cause or consequence of the protective effects of CAPE remains to be elucidated. This critical question will be the topic of further investigations.

In mice treated with CAPE, in the absence of DSS exposure, there were no alterations in MPO or cytokines in the colon and no alterations in colon histology or length. This confirms that in the acute 6-day treatment regimen used in this study, CAPE did not alter physiologic inflammation in normal tissue, but instead suppressed inflammation in the colon when occurred due to DSS-induced disruption of the barrier function.

In this study, we have observed that there was an increase in NF-κB activity in the colon of mice treated with DSS and that CAPE downregulates this increase, thereby exerting a protective event in a mouse model of UC. Since CAPE is a natural compound, with no known side effects (Tambuwala 2016), its therapeutic benefits are obvious and desirable when measured up against other novel compounds with pro-tumorigenic effects; such as DMOG, which have also shown to be protective in experimental colitis (Cummins et al. 2008). The findings of this work indicate that CAPE can be used an effective first-line treatment for patients with UC, improving intestinal barrier function and halting the progression of disease, whilst promoting mucosal healing. The next stage of our work will focus on two elements, namely (1) development of nanoparticle-based colonic drug delivery of CAPE, which could allow for local delivery of the drug to inflamed tissue to ensure effective therapeutic outcomes using a lower dose and (2) identification of the NF-κB subunit most affected by CAPE.
Acknowledgements We wish to thank Ulster University for providing financial support this work in form of Research Challenge Fund (RCF-2014) strategic award.

Conflict with ethical standards

Conflict of interest Authors declare no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References


Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M (2014b) IL-22 from innate lymphoid cells. Mucosal Immunol 7:405–416


Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction...
Author Query Form

Please ensure you fill out your response to the queries raised below and return this form along with your corrections

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the ‘Author’s response’ area provided below

<table>
<thead>
<tr>
<th>Query</th>
<th>Details Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>AQ1</td>
<td>Kindly update the Ref. (Chassaing et al. 2014b) with volume number if possible.</td>
</tr>
</tbody>
</table>